Company Overview and News

 
European shares slip as Trump tweet hits drugmakers

2017-03-07 reuters
LONDON/MILAN, March 7 European shares fell on Tuesday as shares in big international drugmakers were hit after U.S. President Donald Trump tweeted about lowering drug prices.
Upvote Downvote

 
European shares slip for 4th day as Aggreko, Casino sink

2017-03-07 reuters
LONDON, March 7 European shares extended losses on Tuesday on an earnings-heavy day as the biggest fallers Aggreko and Casino were weighed down by results.
Upvote Downvote

 
Banks, earnings, German data keep European stocks in the red

2017-03-07 channelnewsasia
LONDON: European stocks fell for a third consecutive day on Tuesday, once again dragged down by financials as shares in Deutsche Bank slid on deepening concern about its health after its US$8.5 billion cash call.
Upvote Downvote

 
Banks, earnings, German data keep European stocks in the red

2017-03-07 thehindubusinessline
European stocks fell for a third consecutive day on Tuesday, once again dragged down by financials as shares in Deutsche Bank slid on deepening concern about its health after its $8.5 billion cash call.
Upvote Downvote

 
Banks, earnings, German data keep European stocks in the red

2017-03-07 channelnewsasia
LONDON: European stocks fell for a third consecutive day on Tuesday, once again dragged down by financials as shares in Deutsche Bank slid on deepening concern about its health after its US$8.5 billion cash call.
Upvote Downvote

 
European shares slip for 4th straight day as Aggreko, Casino sink

2017-03-07 reuters
LONDON, March 7 European shares extended losses on Tuesday on an earnings-heavy day as the biggest fallers Aggreko and Casino were all weighed down by results.
Upvote Downvote

 
Mittleman Investment Management 2016 Annual Commentary

2017-02-05 valuewalk
Mittleman Investment Management, LLC’s composite dropped 1.1% net of fees in the fourth quarter of 2016, versus gains of 3.8% in the S&P 500 Total Return Index and 8.8% in the Russell 2000 Total Return Index. Longer-term results for our composite through 12/31/16 are presented below:
Upvote Downvote

 
European shares slip, Britain's FTSE 100 at record high

2017-01-09 reuters
LONDON, Jan 9 European shares edged lower on Monday, while a rise among basic resources stocks helped Britain's FTSE 100 index hit a record high.
Upvote Downvote

 
Casino Guichard: A Gamble On Deep Value And A Nice Dividend Yield

2016-09-17 seekingalpha
Casino is number one in multiple countries: Brazil, Colombia, Vietnam and Thailand. And owns the 6th largest listed retailer worldwide.
Upvote Downvote

 
S&P cuts Casino Guichard's debt to junk level

2016-09-17 seekingalpha
S&P Ratings reduces its rating on the debt of Casino Guichard Perrachon (OTC:CGUIF, OTCPK:CGUSY) to junk status. The long-term rating now stands at BB+.
Upvote Downvote

 
Mittleman Brothers Long - ValueWalk

2016-08-01 valuewalk
Mittleman Investment Management Q2 2016 letter some interesting positions including  Rallye where the hedge fund takes issue with Muddy Waters
Upvote Downvote

 
European stocks mostly lower, BoE statement on tap; Dax down 0.02%

2016-04-14 moneycontrol
During European morning trade, the EURO STOXX 50 edged up 0.14%, France's CAC 40 fell 0.18%, while Germany's DAX 30 eased 0.02%.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...